Alzheimer’s Disease Neuroimaging Initiative

ADNI began in October 2004. The overall goal is to validate biomarkers for Alzheimer’s disease clinical trials. One aim is to find, validate and standardize more sensitive and accurate methods to detect Alzheimer’s disease at earlier stages and mark its progress through biomarkers. The study gathered and analyzed thousands of brain scans, genetic profiles, and biomarkers in blood and cerebrospinal fluid that are used to measure the progress of disease or the effects of treatment. More information on ADNI-info.org. All data is publically available at USC/LONI/ADNI.

The three overarching longitudinal ADNI study goals are:

• Validation of biomarkers, especially for amyloid and tau, for use in AD clinical trials.
• To detect Alzheimer’s disease (AD) at the earliest stage possible and identify ways to track the disease through biomarkers.
• To support advances in AD intervention, prevention and treatment through the application of new diagnostic methods to apply at the earliest stages technically possible – when intervention may be most effective.
• To continually develop ADNI’s now- legendary data access policy and continuously improve and expand the unprecedented data sharing model.

Last update – 07/02/2017

Types Neurodegenerative disease-specific cohort
Participant Types Condition diagnosed
Countries Canada|USA
Genders Male and Female
Sample sizes 0 to 4,999
Ages 40 to 59|60 to 100
Brain related measures Behaviour|Cognitive function|Mental health
Funtional rating Individual physiological|Individual psychological
Anthropometric Blood pressure|Height|Weight
Physical Hearing and Vision
Biological samples Blood|Cerebral spinal fluid (CSF)>CSF biomarker data available|Other|Urine
Genotyping Gene screening
Brain imaging Magnetic resonance imaging (MRI)|Positron emission tomography (PET) – amyloid|Positron emission tomography (PET) fluorine18 flurodeoxyglucose (FDG)
Brain banking Consent for brain donation
Lifestyle Smoking
Socio-economic Education|Ethnic group|Family circumstances|Marital status
Health service utilisation
Institute names Northern California Institute for Research and Education
Current Sample Sizes 0 to 4,999

age at recruitment >55
last updated
recruitment period 2004
estimated current sample size number value 1500
cohort acronym ADNI
start date 2004
pi Michael W. Weiner MD
website http://www.adni-info.org/Scientists/ADNIOverview.html
contact details
abstract  ADNI is an ND specific cohort which began in October 2004 recruiting 2,200 participants. The overall goal is to validate biomarkers for Alzheimer’s disease clinical trials.
funders  National Institute on Aging,
National Institute of Health,
Foundation for NIH (FNIH)
contact email [email protected]
contact phone number +11 31 415 750-2146
estimated current sample size 0 to 4,999
sample sizes 2200